Pain management in Guillain-Barre syndrome: A systematic review
Objetivo: Material y métodos: Resultados: Conclusiones: Introduction: Pain is a common symptom in patients with Guillain-Barre syndrome. Intensity is moderate to severe in most cases and pain may persist after resolution of the disease. Objective: Identify the most appropriate analgesic therapy for...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2015
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/22656
- Acceso en línea:
- https://doi.org/10.1016/j.nrl.2014.04.009
https://repository.urosario.edu.co/handle/10336/22656
- Palabra clave:
- Analgesic agent
Carbamazepine
Gabapentin
Methylprednisolone
4 aminobutyric acid
Amine
Analgesic agent
Antiinflammatory agent
Carbamazepine
Cyclohexanecarboxylic acid derivative
Methylprednisolone
Analgesia
Drug efficacy
Guillain barre syndrome
Human
Randomized controlled trial (topic)
Short survey
Systematic review
Guillain-barre syndrome
Amines
Analgesics
Anti-inflammatory agents
Carbamazepine
Cyclohexanecarboxylic acids
Gamma-aminobutyric acid
Guillain-barre syndrome
Humans
Methylprednisolone
Pain management
Carbamazepine
Gabapentin
Guillain-barre syndrome
Methylprednisolone
Pain
Systematic reviews
- Rights
- License
- Abierto (Texto Completo)
Summary: | Objetivo: Material y métodos: Resultados: Conclusiones: Introduction: Pain is a common symptom in patients with Guillain-Barre syndrome. Intensity is moderate to severe in most cases and pain may persist after resolution of the disease. Objective: Identify the most appropriate analgesic therapy for pain management in patients with Guillain-Barre syndrome. Material and methods: Systematic review and selection of scientific articles on treatment of pain in Guillain-Barre syndrome patients, published between January 1985 and December 2012. We included only randomised, double-blind, controlled trials assessing the effectiveness of drugs for pain management in these patients. Results: Four articles met the inclusion criteria. One evaluated the use of gabapentin, another evaluated carbamazepine, a third compared gabapentin to carbamazepine, and the last evaluated use of methylprednisolone. Both carbamazepine and gabapentin were useful for pain management. Patients experienced lower-intensity pain with gabapentin treatment in the study comparing that drug to carbamazepine. Methylprednisolone was not shown to be effective for reducing pain. The published data did not permit completion of a meta-analysis. Conclusions: There is no robust evidence at present that would point to a single treatment option for this disorder. Further clinical studies of larger patient samples and with a longer duration are needed to characterise types of pain for each patient and measure pain intensity in an objective way. © 2013 Sociedad Española de Neurología. |
---|